Spiro-Substituted Compounds for Irreversible Tyrosine Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with angiogenesis, such as cancer, lack effective inhibitors for protein tyrosine kinases, particularly VEGF, which are involved in tumor growth and vascular permeability.
Innovation Solution
Development of spiro-substituted compounds that inhibit protein tyrosine kinases, including VEGFr, EGFr, and others, acting as irreversible inhibitors to reduce angiogenesis and tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for angiogenesis-associated diseases are used, then disease management is maintained, but effective inhibition of protein tyrosine kinases (particularly VEGF) is lacking, resulting in insufficient tumor growth control and vascular permeability reduction
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of tyrosine kinase inhibitors through spiro-substituted compounds with specific molecular configurations (formula I). These structural parameter changes result in compounds with optimized binding affinity and irreversible inhibition characteristics, thereby improving the reliability of kinase inhibition while enhancing tumor growth control and vascular permeability reduction effects
Solution Approach 2:
The invention utilizes composite material principles by designing spiro-substituted compounds that combine multiple functional groups and structural elements (including spiro rings, aromatic systems, and substituent variations) into a single molecular entity. This composite molecular structure achieves superior inhibition efficacy against multiple protein tyrosine kinases simultaneously, addressing the limitation of current single-target inhibitors
2Reliability
If spiro-substituted compounds are developed as irreversible inhibitors, then inhibition efficacy against protein tyrosine kinases is significantly improved, but the complexity of compound structure and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the complex spiro-substituted compound into modular structural components defined in formula I, where different substituents (R1-R6, A, B, X, W, Z, G, a, b, c) can be independently varied. This modular approach allows systematic optimization of inhibition efficacy while managing synthesis complexity through standardized building blocks and substituent libraries
Solution Approach 2:
The invention achieves universality by designing a core spiro-substituted molecular scaffold (formula I) that can inhibit multiple protein tyrosine kinases including VEGFR, EGFR, and others. The universal scaffold with variable substituents provides multi-functional inhibition capability, improving reliability across different kinase targets while avoiding the need to develop separate compounds for each kinase
Data Source
AI summary
(I) The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.